Boundless Bio snags $105m Series B

Boundless Bio, a next-generation precision oncology company, has secured $105 million in Series B financing.

Boundless Bio, a next-generation precision oncology company, has secured $105 million in Series B financing. RA Capital Management and Nextech Invest led the round.

Source: Press Release